Lyka Labs Limited (IN:LYKALABS)
:LYKALABS
Want to see IN:LYKALABS full AI Analyst Report?
Top Page
Lyka Labs Limited
(LYKALABS)
Select Model
Select Model
Rating:59Neutral
Price Target:
₹63.00
▼(-33.26% Downside)
Action:ReiteratedDate:04/24/26
The score is driven primarily by improving operating performance and revenue growth, tempered by weak cash generation and negative free cash flow. Technicals are only mildly supportive with neutral momentum and a still-weak longer-term trend, while valuation is a major drag due to an unusable negative P/E and no dividend yield data.
Positive Factors
Strong revenue growth and improving margins
Sustained top-line growth alongside rising EBIT/EBITDA margins indicates improving operational efficiency and pricing or mix gains. That combination supports durable earnings power, allowing reinvestment into capacity and product development over the coming several quarters.
Negative Factors
Weak cash generation and negative free cash flow
Negative free cash flow and low cash conversion of profits constrain the company's ability to self-fund expansion, approvals or working-capital needs. Continued capex-driven outflows may force external financing or delay strategic investments in the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth and improving margins
Sustained top-line growth alongside rising EBIT/EBITDA margins indicates improving operational efficiency and pricing or mix gains. That combination supports durable earnings power, allowing reinvestment into capacity and product development over the coming several quarters.
Read all positive factors
Lyka Labs Limited (LYKALABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.16B
Dividend YieldN/A
Average Volume (3M)3.02K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth0.76%
EPS Growth-116.54%
CountryIN
Employees423
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding35,690,000
10 Day Avg. Volume1,252
30 Day Avg. Volume3,017
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.58
Price to Sales (P/S)2.64
P/FCF Ratio-26.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lyka Labs Limited Business Overview & Revenue Model
Company Description
Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells v...
How the Company Makes Money
Lyka Labs Limited primarily makes money by selling pharmaceutical products, including (1) finished dosage formulations (such as tablets, capsules, injectables, or similar dosage forms) and (2) active pharmaceutical ingredients (APIs) supplied to o...
Lyka Labs Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
68
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38B | 1.41B | 1.05B | 916.90M | 1.84B | 671.07M |
| Gross Profit | 714.24M | 851.35M | 599.41M | 152.84M | 1.30B | 289.23M |
| EBITDA | 140.68M | 201.67M | 167.59M | 128.47M | 1.01B | 201.17M |
| Net Income | 20.55M | 80.12M | -24.89M | -132.12M | 390.00M | -115.55M |
Balance Sheet | ||||||
| Total Assets | 1.68B | 1.76B | 1.57B | 1.52B | 1.86B | 1.90B |
| Cash, Cash Equivalents and Short-Term Investments | 11.89M | 13.63M | 62.91M | 119.39M | 170.59M | 76.30M |
| Total Debt | 316.57M | 391.84M | 586.50M | 751.02M | 1.30B | 1.63B |
| Total Liabilities | 664.32M | 726.24M | 884.59M | 1.06B | 1.72B | 2.15B |
| Stockholders Equity | 1.01B | 1.04B | 681.54M | 454.41M | 133.38M | -257.97M |
Cash Flow | ||||||
| Free Cash Flow | 51.46M | -137.55M | -74.58M | 7.67M | 717.33M | 75.44M |
| Operating Cash Flow | 136.84M | 18.99M | 17.73M | 89.53M | 792.46M | 88.11M |
| Investing Cash Flow | -46.95M | -117.96M | -94.88M | 73.50M | -61.72M | -1.61M |
| Financing Cash Flow | -91.69M | 52.92M | 19.53M | -216.43M | -631.77M | -117.98M |
Lyka Labs Limited Technical Analysis
Positive
94.40
Price Trends
60.19
Negative
69.03
Negative
85.42
Negative
Market Momentum
-0.31
Negative
53.05
Neutral
55.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LYKALABS, the sentiment is Positive. The current price of 94.4 is above the 20-day moving average (MA) of 53.96, above the 50-day MA of 60.19, and above the 200-day MA of 85.42, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 53.05 is Neutral, neither overbought nor oversold. The STOCH value of 55.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LYKALABS.
Lyka Labs Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹55.90B | 30.45 | ― | 0.13% | 9.68% | 6.17% | |
69 Neutral | ₹4.46B | 13.96 | ― | 0.12% | 0.63% | -13.85% | |
61 Neutral | ₹28.79B | -74.58 | ― | ― | 5.55% | ― | |
59 Neutral | ₹2.16B | -338,564.26 | ― | ― | 0.76% | -116.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹22.14B | 144.78 | ― | ― | 7.55% | 1.64% | |
46 Neutral | ₹39.77B | -40.91 | ― | 0.06% | 92.70% | -28.06% |
* Healthcare Sector Average
IN:LYKALABS
Lyka Labs Limited
60.49
-49.66
-45.08%
IN:DCAL
Dishman Carbogen Amcis Ltd.
183.60
-9.80
-5.07%
IN:PANACEABIO
Panacea Biotec Limited
361.50
-183.65
-33.69%
IN:HALEOSLABS
SMS Lifesciences India Ltd.
1,474.90
125.74
9.32%
IN:SUPRIYA
Supriya Lifescience Limited
694.50
57.02
8.94%
IN:ZOTA
Zota Health Care Ltd.
1,311.20
420.07
47.14%
Lyka Labs Limited Corporate Events
Lyka Labs Completes Amalgamation With Lyka Exports, Boosts Authorised Capital
Apr 9, 2026
Lyka Labs Limited has secured final approval for the amalgamation of group entity Lyka Exports Limited, after the National Company Law Tribunal in Ahmedabad sanctioned the merger and the order was filed with the Registrar of Companies. The scheme,...
NCLT Clears Merger of Lyka Exports With Lyka Labs
Mar 17, 2026
Lyka Labs Limited has announced that the National Company Law Tribunal, Ahmedabad Bench, has approved the amalgamation of Lyka Exports Limited with Lyka Labs under sections 230 to 232 of the Companies Act, 2013. The scheme, with an appointed date ...
Lyka Labs Says NCLT Reserves Order on Amalgamation Scheme After FEMA Compliance Filing
Feb 20, 2026
Lyka Labs Limited has updated exchanges on the status of its proposed scheme of amalgamation, noting that the National Company Law Tribunal has examined its filings on compliance with foreign exchange and import-export regulations. The company rep...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.